Reference number(s)
2978-H

SPECIALTY QUANTITY LIMIT PROGRAM

MAKENA (hydroxyprogesterone caproate)
hydroxyprogesterone caproate (generic)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
hydroxyprogesterone caproate/Makena 250 mg/mL single dose vial (1 mL)	21 vials per 365 days	250 mg intramuscularly once weekly (every 7 days) Continue once weekly until week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever occurs first
hydroxyprogesterone caproate/Makena 250 mg/mL multi-dose vial (5 mL)	5 vials per 365 days	
Makena 275 mg/1.1 mL auto-injector	21 syringes per 365 days	275 mg subcutaneously once weekly (every 7 days) Continue once weekly until week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever occurs first

III. REFERENCES

1. Makena [package insert]. Waltham, MA: AMAG Pharmaceuticals; February 2018.
2. Hydroxyprogesterone caproate [package insert]. Shirley, NY. American Regent, Inc; July 2018.

CVS caremark™